All bioresorbable vascular grafts, constructed from a nonwoven poly(glycolic acid) fiber mesh coated with a 50:50 copolymer sealant solution of poly(L-lactide-co-ε-caprolactone) as previously described, 1 were provided by Gunze Ltd. Each graft was 3.00 mm in length with an inner diameter of 1.06 mm.
Surgical implantation of bioresorbable vascular grafts
Bioresorbable vascular grafts were implanted in 8-10 weeks old female mice (n=25 for each group) as inferior vena cava interposition grafts using standard microsurgical techniques as previously described. 5 No medications except for the drugs under investigation were administrated at any point during this study. Mice were sacrificed either 2 weeks (n=10 per group) or 24 weeks (n=15 per group) after implantation, and grafts were explanted for analysis.
Serial monitoring of implanted grafts by ultrasound
Ultrasonography (Vevo Visualsonics 2100; Visualsonics) was employed to monitor the patency of implanted grafts at 8, 16, and 24 weeks after implantation. Mice were anesthetized with 1.5% inhaled isoflurane during ultrasound measurements.
Histology and immunohistochemistry
Explanted grafts were fixed in 4% para-formaldehyde, embedded in paraffin, sliced (5 μm thick sections), and stained with Hematoxylin and Eosin (HE), Masson's Trichrome, Alcian Blue, and Hart's. Collagen deposition was assessed with Picrosirius red staining and images were obtained with polarized light microscopy. The proportion of collagen type I (orange to yellow) and collagen type III (green) in neotissue at the 2-and 24-week time points was measured with Image J software (NIH).
Identification of smooth muscle cells (SMCs), monocytes/macrophages, and activated inflammatory cells was accomplished by immunohistochemical staining of paraffin-embedded explant sections with anti-α-smooth muscle actin (α-SMA), 1A4 (1:500, DAKO), anti-F4/80, CI:A3-1 (1:1000, AbD Serotec), and anti-inducible nitric oxide synthase (iNOS) (1:20, ab3523, Abcam), respectively. Primary antibody binding was detected using species appropriate biotinylated IgG (Vector), and this was followed by the binding of streptavidin-horse radish peroxidase (Vector) and color development with 3,3-diaminobenzidine (Vector). Light field images were obtained with a Zeiss Axio Imager.A2 microscope (Carl Zeiss).
SMCs identified by α-SMA expression, F4/80 positive monocytes/macrophages, and activated inflammatory cells identified by iNOS positive staining were quantified by manual counting. One representative section from each explant was stained and imaged. Low magnification (5x) images were divided into nine sections (3x3). Four of these regions (upper middle, center, lower right, and lower left) were selected to obtain high magnification (20x) images, the area of which was 0.12 mm 2 . All positively stained nuclei were counted from high magnification images. Averages from these four regions represented the number of positive cells in each section.
Immunofluorescent staining for CD31 as a marker of endothelial cells, α-SMA and smooth muscle-myosin heavy chain (SM-MHC) as markers of SMCs, and collagen type IV was performed using anti-CD31 antibody (1:50, ab28364, Abcam), anti-α-SMA, 1A4 (1:500, DAKO) anti-SM-MHC antibody, 1G12 (1:400, Abcam), and anti-collagen IV (1:500, ab6586, Abcam) followed by Alexa Fluor 647 anti-mouse IgG secondary antibody (1:300, ab150115, Invitrogen) or Alexa Fluor 488 anti-rabbit IgG secondary antibody (1:300, ab150077, Invitrogen), respectively. Fluorescence images were obtained with an Olympus IX51 microscope (Olympus).
Morphometric analysis
Outer and luminal perimeters of graft explants were manually measured from HE staining with Image J software (NIH) to obtain luminal diameter and wall thickness measurements. A patent graft was defined as having a luminal diameter greater than 0.53 mm, equivalent to 50% of the inner diameter of the graft at the time of implantation.
RNA extraction and reverse transcriptase-quantitative polymerase chain reaction
Total RNA was extracted from frozen samples and purified using the RNeasy mini kit (74104, Qiagen). Reverse transcription was performed using the High Capacity RNA-to-cDNA Kit (4387406, Applied Biosystems) to obtain complementary DNA for polymerase chain reaction (PCR) assay. All reagents and instrumentation for quantitative PCR were obtained from Applied Biosystems. Reverse transcriptase-quantitative PCR was performed with a Step One Plus RealTime PCR System using the TaqMan Universal PCR Master Mix Kit per the manufacturer's instructions. Reference numbers for primers are: PECAM-1 (Mm01242584_m1), eNOS (Mm00435217_m1), and HPRT (Mm00446968_m1).
The quantitative PCR data was analyzed using the comparative threshold cycle method and normalized to the expression of HPRT as an endogenous reference. Results are reported as relative values (ΔΔ CT) to those of the no treatment control group.
Tissue digestion to obtain cells from implanted grafts
The grafts harvested from each group at the 2-week time point were minced into small pieces with scissors and digested in a HBSS solution containing 1 mg/ml collagenase type IV, 0.2 mg/ml DNase I, 200 U/ml hyaluronidase, and 1 mg/ml bovine serum albumin/fraction V (invitrogen). Cells were filtered (40 μm cell filter, BD Bioscience) to remove remaining graft debris. After counting the number of cells obtained from each graft using Trypan blue exclusion with a manual hemocytometer, cells were stained for flow cytometry.
Monocyte isolation from bone marrow cells and inflammatory stimulation
Bone marrow cell suspensions were isolated by flushing femurs and tibias of 8-10 weeks old C57BL/6 mice with complete RPMI1640 (+10% FCS, +1% Pen/Strep). Cell suspensions were diluted 5:1 with Hank's balanced salt solution, overlaid on Ficoll solution (Histopaque 1083, density 1.083 g/ml, 10831, Sigma) and centrifuged for 45 min at 500 g, at room temperature. The mononuclear cell interface was collected and washed two times in HBSS. Cells were incubated with a mixture of antibody MicroBeads according to the manufacturer's protocol (130-100-629, Miltenyi Biotec). The cells were then run through a LD-negative selection column. The negative fraction was collected (monocytes), and cultured in complete RPMI1640. Cultures of purified monocytes were stimulated overnight with lipopolysaccharide (100 ng/ml, L2630, Sigma) and interferon gamma (10 ng/ml, 575302, BioLegend) in absence or presence of aspirin (3.0μM, 10μM and 30μM) (A5376, Sigma) or cilostazol (10μM, 50μM and 100μM) (C0737, Sigma).
Flow cytometric analysis of macrophage lineage cells
Harvested cells from grafts or bone marrow were incubated in saturated doses of anti-mouse Fc receptor antibody in 100uL PBS 0.5% BSA 0.02% NaN3 (FACS buffer) for 15 min on ice. After washing, 1-3 x 10 6 cells were stained in FACS buffer for 15 min 4 °C with various fluorescent mAb combinations and further collected on a LSR II cytofluorometer (BD Bioscience). Cells were gated according to size and scatter to eliminate debris. Blue-fluorescent reactive dye, L23105 (Life Technologies) was used to discriminate dead cells. The following antibodies were used for extracellular staining: anti -CD11b-Alexa Fluor 700, M1/70 (BioLegend); anti -CD115-PE-Cy7, AFS98 (eBiosciences); anti-F4/80-Brilliant violet 605, BM8 (BioLegend); anti Ly6G-PER-CP, 1A8 (BioLegend); anti-Ly6C-PE-Cy7, HK1.4 (BioLegend); anti-Ly-6C-eFluor 450, HK1.4 (eBioscience); anti-F4/80-PE-Cy7, BM8 (eBioscience); anti-CD45-Brilliant Violet 605, 30-F11 (BioLegend) and anti-F4/80-FITC, BM8 (BioLegend).
For intracellular staining, cells were washed with FACS buffer and stained according to the protocol of the cytofix/cytoperm kit (554714, BD Biosciences) and stained using anti-iNOS-PE, CXNFT (eBiosciences). Compensation and data analysis was performed using FlowJo software (Tree Star).
